Successful Treatment-Free Remission After Ponatinib Discontinuation in Pretreated Patients with Chronic Myeloid Leukemia in Chronic Phase
Clinical Lymphoma Myeloma and Leukemia · 2025
DOI: 10.1016/j.clml.2024.11.003 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma Myeloma and Leukemia, 2025. Verfasst von Fadi G Haddad und 7 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas. Electronic address: fhaddad@mdanderson.org. Hauptthemen laut MEDLINE: Imidazoles, Pyridazines, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Protein Kinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH.
Abstract (Originalsprache)
INTRODUCTION: The discontinuation of third-generation BCR::ABL1 tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia in chronic phase (CML-CP) is not well understood. We aim to evaluate treatment-free remission in patients with CML-CP who discontinue ponatinib. METHODS: We retrospectively reviewed 361 patients who attempted TKI discontinuation between November 2005 and February 2024 and identified those receiving ponatinib at the time of discontinuation. Molecular relapse-free survival (MRFS) was calculated from the time of ponatinib discontinuation to the date of loss of major molecular response (MMR) or last follow-up. RESULTS: Eleven patients discontinued ponatinib. Before ponatinib discontinuation, patients were on TKI therapy for a median of 146.6 months and on ponatinib for a median of 67.5 months. The median number of TKIs prior to starting ponatinib was 2 (range, 1-3). The median durations of sustained MR4 and MR4.5 before ponatinib discontinuation were 32.8 and 29.4 months, respectively. After a median follow-up of 60.3 months, the 60-month MRFS rate was 53%. Five patients lost MMR; their median MR4.5 duration was 5 months before ponatinib discontinuation. CONCLUSION: Ponatinib discontinuation is feasible in patients with CML-CP failing prior TKIs. Patients who achieve sustained MR4.5 for at least 2 years have the highest likelihood of remaining in treatment-free remission following ponatinib discontinuation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departments of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas. Electronic address: fhaddad@mdanderson.org.
- Departments of Leukemia, The University of Texas, MD Anderson Cancer Center, Houston, Texas.
- Hematopathology, The University of Texas, MD Anderson Cancer Center, Houston, Texas.
Förderung
- NCI NIH HHS
- NIH
Zitieren
APA
Haddad, F. G., Sasaki, K., Senapati, J., Hu, S., Dellasala, S., Issa, G. C., Jabbour, E., & Kantarjian, H. (2025). Successful Treatment-Free Remission After Ponatinib Discontinuation in Pretreated Patients with Chronic Myeloid Leukemia in Chronic Phase. Clinical Lymphoma Myeloma and Leukemia. https://doi.org/10.1016/j.clml.2024.11.003
Vancouver
Haddad FG, Sasaki K, Senapati J, Hu S, Dellasala S, Issa GC, et al. Successful Treatment-Free Remission After Ponatinib Discontinuation in Pretreated Patients with Chronic Myeloid Leukemia in Chronic Phase. Clinical Lymphoma Myeloma and Leukemia. 2025. doi:10.1016/j.clml.2024.11.003
BibTeX
@article{Haddad2025,
author = {Haddad, Fadi G and Sasaki, Koji and Senapati, Jayastu and Hu, Shimin and Dellasala, Sara and Issa, Ghayas C and Jabbour, Elias and Kantarjian, Hagop},
title = {Successful Treatment-Free Remission After Ponatinib Discontinuation in Pretreated Patients with Chronic Myeloid Leukemia in Chronic Phase},
journal = {Clinical Lymphoma Myeloma and Leukemia},
year = {2025},
doi = {10.1016/j.clml.2024.11.003}
}
EUVIMED